Anthony Tak Cheung Chan

Anthony Tak Cheung Chan

Top Cited Scholar 2026
Auto-generated profile, based on publicly available information

Anthony Tak Cheung Chan

State Key Laboratory of Translational Oncology, Sir YK Pao Centre for Cancer, Department of Clinical Oncology, Hong Kong Cancer Institute, The Chinese University of Hong Kong, Hong Kong, Special Administrative Region, People’s Republic of China

Research Focus & Metrics

Academic Career Length

35Years (1992-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 July 2019 in The Lancet
Verified
Journal Article
Closed access
YCYu-Pei Chen
Yu-Pei Chen
ACAnthony T C Chan
Anthony T C Chan
QLQuynh-Thu Le
Quynh-Thu Le
PBPierre Blanchard
Pierre Blanchard
YSYing Sun
Ying Sun
JMJun Ma
Jun Ma

1 March 2016 in The Lancet
Verified
Journal Article
Closed access
MCMelvin L K Chua
Melvin L K Chua
JWJoseph T S Wee
Joseph T S Wee
EHEdwin P Hui
Edwin P Hui
ACAnthony T C Chan
Anthony T C Chan

10 August 2017 in New England Journal of Medicine
Verified
Journal Article
Closed access
PDF file
KCKwan Chee Allen Chan
Kwan Chee Allen Chan
JWJohn K.S. Woo
John K.S. Woo
AKAnn D. King
Ann D. King
BZBenny Chung-Ying Zee
Benny Chung-Ying Zee
WLWai Kei Jacky Lam
Wai Kei Jacky Lam
YLY. M. Dennis Lo
Y. M. Dennis Lo
Circulating cell-free Epstein–Barr virus (EBV) DNA is a biomarker for nasopharyngeal carcinoma. We conducted a prospective study to investigate whether EBV DNA in plasma samples would be useful to screen for early nasopharyngeal carcinoma in asymptomatic persons.

10 October 2015 in Journal of Clinical Oncology
Verified
Journal Article
Closed access
ALAnne W.M. Lee
Anne W.M. Lee
Brigette Buig Yue MaBrigette Buig Yue Ma
Brigette Buig Yue Ma
WNWai Tong Ng
Wai Tong Ng
ACAnthony T.C. Chan
Anthony T.C. Chan
Nasopharyngeal carcinoma of the undifferentiated subtype is endemic to southern China, and patient prognosis has improved significantly over the past three decades because of advances in disease management, diagnostic imaging, radiotherapy technology, and broader application of systemic therapy. Despite the excellent local control with modern radiotherapy, distant failure remains a key challenge. Advances in molecular technology have helped to decipher the molecular pathogenesis of nasopharyngeal carcinoma as well as its etiologic association with the Epstein-Barr virus. This in turn has led to the discovery of novel biomarkers and drug targets, rendering this cancer site a current focus for new drug development. This article reviews and appraises the key literature on the current management of nasopharyngeal carcinoma and future directions in clinical research.

1 June 2015 in The Lancet Oncology
Verified
Journal Article
Closed access
PBPierre Blanchard
Pierre Blanchard
ALAnne Lee
Anne Lee
SMSophie Marguet
Sophie Marguet
JLJulie Leclercq
Julie Leclercq
WNWai Tong Ng
Wai Tong Ng
JPJean Pierre Pignon
Jean Pierre Pignon

1 November 2007 in Journal of Clinical Oncology
Verified
Journal Article
Closed access
PDF file
MKMichael K.M. Kam
Michael K.M. Kam
SLSing-Fai Leung
Sing-Fai Leung
BZBenny Chung-Ying Zee
Benny Chung-Ying Zee
RCRicky M.C. Chau
Ricky M.C. Chau
JSJoyce J.S. Suen
Joyce J.S. Suen
ACAnthony T.C. Chan
Anthony T.C. Chan
Purpose This randomized trial compared the rates of delayed xerostomia between two-dimensional radiation therapy (2DRT) and intensity-modulated radiation therapy (IMRT) in the treatment of early-stage nasopharyngeal carcinoma (NPC). Patients and Methods Between November 2001 and December 2003, 60 patients with T1-2bN0-1M0 NPC were randomly assigned to receive either IMRT or 2DRT. Primary end point was incidence of observer-rated severe xerostomia at 1 year after treatment based on Radiotherapy Oncology Group /European Organisation for the Research and Treatment of Cancer late radiation morbidity scoring criteria. Parallel assessment with patient-reported outcome, stimulated parotid flow rate (SPFR), and stimulated whole saliva flow rate (SWSFR) were also made. Results At 1 year after treatment, patients in IMRT arm had lower incidence of observer-rated severe xerostomia than patients in the 2DRT arm (39.3% v 82.1%; P = .001), parallel with a higher fractional SPFR (0.90 v 0.05; P < .0001), and higher fractional SWSFR (0.41 v 0.20; P = .001). As for patient's subjective feeling, although a trend of improvement in patient-reported outcome was observed after IMRT, recovery was incomplete and there was no significant difference in patient-reported outcome between the two arms. Conclusion IMRT is superior to 2DRT in preserving parotid function and results in less severe delayed xerostomia in the treatment of early-stage NPC. Incomplete improvement in patient's subjective xerostomia with parotid-sparing IMRT reflects the need to enhance protection of other salivary glands.